Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with mesothelioma~* Previously treated with only one course of chemotherapy for mesothelioma~* No previous treatment with vinorelbine~* No serious heart problems within the last 3 months~Exclusion Criteria:~* Serious abnormal laboratory values~* Severe or uncontrolled disease or condition as judged by the Investigator~* Pregnant or breast-feeding women~* Other cancers within the last 5 years~* Major surgery or radiation therapy within 4 weeks prior to starting study therapy~* Receipt of any investigational agents within 30 days prior to commencing study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Vinorelbine
- 2 (Type: EXPERIMENTAL): Vandetanib

Based on this trial design, predict the completion outcome and termination type (if applicable).